• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Thursday, May 19, 2022
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Drug reduces seizure frequency in children with tuberous sclerosis complex

Bioengineer by Bioengineer
September 7, 2016
in Health
1
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
Jacqueline French
Jacqueline French, MD, professor of neurology and director of Translational Research & Clinical Trials Epilepsy at NYU Langone’s Comprehensive Epilepsy Center

In an international study, the drug everolimus has been shown to significantly reduce the frequency of seizures in patients with treatment-resistant epilepsy and tuberous sclerosis complex (TSC) — a genetic disease that causes malformations and tumors in the brain and other vital organs.

The phase 3 study, published online in The Lancet, is the latest to show the effectiveness of everolimus in slowing the cell growth that is overactive in patients with TSC.

“The median percentage reduction in seizure frequency was more than 29 percent for patients on a low-dose regimen of everolimus and nearly 40 percent for patients with high-dose regimen to the drug,” says David Franz, MD, founding director of the TSC Clinic at Cincinnati Children’s Hospital Medical Center and the study’s senior author. “At baseline, nearly half of patients had failed treatment with six or more previous antiepileptic drugs.”

The lead author of the study was Jacqueline French, MD, professor of neurology and director of Translational Research & Clinical Trials Epilepsy at NYU Langone’s Comprehensive Epilepsy Center.

The phase III study was conducted among 366 patients with TSC and epilepsy from 25 countries who were randomly assigned to either a placebo, a low dose of everolimus or a higher dose. Patients ranged in age from two to 65.

Serious adverse events occurred in 3 percent of patients who received placebo and 14 percent of those who received a low-dose or high-dose of everolimus. The number of severe adverse events and events leading to discontinuation of the study was consistent with findings of previous studies of everolimus, according to Dr. Franz.

Everolimus has previously been shown to reduce the volume of subependymal giant-cell astrocytomas (low-grade grain tumors and angiomyolipomas (non-cancerous tumors) in the kidneys of patients with TSC. It also has been shown to improve the appearance of skin lesions in patients with TSC.

The same mTOR pathway associated with overactive cell growth in TSC also is implicated in other cancers and neurological conditions, such as Alzheimer’s disease, type 2 diabetes, Parkinson’s disease, Huntington’s disease and autism. This makes everolimus, an mTOR inhibitor, a potential candidate to treat these mTOR-associated disorders, says Dr. Franz.

Nearly 50,000 children and adults in the United States and approximately a million people around the world live with TSC. The TSC Clinic at Cincinnati Children’s is believed to be the largest in the world. The multidisciplinary clinic team follows more than 1,000 children and adults with tuberous sclerosis and manages every aspect of the disorder.

Everolimus is marketed by Novartis, which provided drug and financial support for the study. In addition, several of the study authors are employees of Novartis.

###

About Cincinnati Children’s

Cincinnati Children’s, a non-profit, pediatric, academic medical center established in 1883, is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education and innovation. It is one of the top three recipients of pediatric research grants from the National Institutes of Health, ranked third in the nation among all Honor Roll hospitals in U.S. News and World Report’s Best Children’s Hospitals, and a research and teaching affiliate of the University of Cincinnati’s College of Medicine. Its patient population includes the eight-county primary service area covering parts of Ohio, Kentucky and Indiana. A destination for children with complex medical conditions, it also served patients from all 50 states and nearly 70 countries during the past year. Additional information can be found at http://www.cincinnatichildrens.org. Connect on the Cincinnati Children’s blog, via Facebook and on Twitter.

Media Contact

Jim Feuer
[email protected]
513-636-4656
@CincyChildrens

http://www.cincinnatichildrens.org

The post Drug reduces seizure frequency in children with tuberous sclerosis complex appeared first on Scienmag.

Share20Tweet7Share2ShareShareShare1

Related Posts

Scripps Research awarded $67 million by NIH to lead new Pandemic Preparedness Center

Scripps Research awarded $67 million by NIH to lead new Pandemic Preparedness Center

May 18, 2022
SARS-CoV-2 virus particles

NIAID announces antiviral drug development awards

May 18, 2022

Childhood circumstances and personality traits are associated with loneliness in older age

May 18, 2022

How three mutations work together to spur new SARS-CoV-2 variants

May 18, 2022
Please login to join discussion

POPULAR NEWS

  • Weybourne Atmospheric Observatory

    Breakthrough in estimating fossil fuel CO2 emissions

    46 shares
    Share 18 Tweet 12
  • Hidden benefit: Facemasks may reduce severity of COVID-19 and pressure on health systems, researchers find

    44 shares
    Share 18 Tweet 11
  • Discovery of the one-way superconductor, thought to be impossible

    43 shares
    Share 17 Tweet 11
  • Sweet discovery could drive down inflammation, cancers and viruses

    43 shares
    Share 17 Tweet 11

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

University of WashingtonVirologyVehiclesZoology/Veterinary ScienceVaccinesUrogenital SystemUrbanizationWeaponryVirusVaccineViolence/CriminalsWeather/Storms

Recent Posts

  • Recycling more precious metals from nuclear and electronic waste using the Picasso pigment, Prussian blue
  • Buck Scientist uncovers clues to aging in mitochondria
  • Scripps Research awarded $67 million by NIH to lead new Pandemic Preparedness Center
  • NIAID announces antiviral drug development awards
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Posting....